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The failure to restore a normal Thrombolysis In Myocardial
Infarction (TIMI) ﬂow after primary percutaneous coronary
intervention (PCI) for acute myocardial infarction (AMI)
despite a patent infarct artery is associated with increased
mortality. Recent trials on primary PCI show thatw10% of
patients have no-reﬂow or slow-reﬂow after primary PCI,
and all studies show that no-ﬂow or slow-reﬂow is a strong
predictor of mortality (1–3).See page 2088Embolization and ischemic disruption of the microvessel
network and the subsequent no-/slow-reﬂow may occur
spontaneously, during recanalization of the infarct vessel
by wiring and balloon angioplasty, or after infarct artery
stenting. The deterioration of TIMI grade 3 ﬂow after
stenting is a good model of procedural no-/slow-reﬂow in-
dependent of the variables associated with an already dis-
rupted microvessel network at the time of intervention
(totally occluded infarct artery, long time from symptom
onset to recanalization, lack of collateral ﬂow), shows the
detrimental effect of atherothrombotic material emboliza-
tion, and supports the rationale for all mechanical and
pharmacological treatments that may reduce or eliminate
the thrombus burden.
The Deferred Stent Trial in STEMI is a randomized
mechanistic trial that used an original approach to throm-
bus removal or reduction before infarct artery stenting (4).
In this issue of the Journal, the investigators hypothesized
that after initial achievement of a normal TIMI ﬂow by
wiring, nonaggressive balloon angioplasty, or aspiration, a
brief deferral of stenting and simultaneous infusion of
glycoprotein IIb/IIIa and low molecular weight heparin
could result in a decreased thrombotic burden and risk of
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They compared the strategy of deferred stenting with im-
mediate stenting in 101 patients with AMI at high risk of
no-/slow-reﬂow identiﬁed by clinical, electrocardio-
graphic, and angiographic variables that are known to be
predictors of no-/slow-reﬂow.
The deferred stenting strategy resulted in a dramatic
decrease in no-/slow-reﬂow rate (5.9% vs. 28.6%, odds ratio:
0.16, 95% conﬁdence interval: 0.03 to 0.63; p ¼ 0.005),
and, more importantly, the prevention of the no-/slow-
reﬂow according to the mechanistic design of the study
was associated with improved myocardial reperfusion and
myocardial salvage as shown by all angiographic, electro-
cardiographic, and magnetic resonance imaging (MRI)
parameters. Myocardial salvage, deﬁned as the difference
between the initial jeopardized area at risk at baseline
and ﬁnal infarct size revealed at 6 months by MRI was
greatly improved in the deferred stenting patient group
(14.7% vs. 19.7%; p ¼ 0.027). The quality of this ﬁnding is
very high considering that most of randomized patients
had paired MRI (at 2 days and 6 months), and the MRI
follow-up rate was very impressive (98%).
Recurrence of AMI due to infarct artery reocclusion in
the deferred stent group was very low; only 2 patients had
reocclusion of the infarcted artery, and both were treated
successfully with bail-out stenting. There was no increase
in major bleeding or contrast-induced nephropathy in the
deferred stenting group. Thus, despite the small number of
patients and events, it is likely that the strategy of deferred
stenting is safe. If conﬁrmed by ongoing trials on deferred
stenting, glycoprotein IIb/IIIa inhibitors will assume again
a central role in primary PCI, not only for the reduction
of thrombotic burden, but also for the prevention of new
thrombotic occlusion if a deferred stenting strategy is
adopted. Prolonged infusion of glycoprotein IIb/IIIa inhibi-
tor is able to prevent no-/slow-reﬂow in the deferred stenting
arm, resulting in increased myocardial salvage compared
with the immediate stenting group, and it is notable that
nearly all patients of the immediate stenting arm (98.9%)
received the same antithrombotic treatment after immediate
stenting, avoiding the potential for a confounding effect of
prolonged infusion of heparin and glycoprotein IIb/IIIa
inhibitor on ﬁnal infarct size and myocardial salvage.
Another strength of the study is the collection of data
of screened nonrandomized patients in a parallel registry.
The registry included both eligible and noneligible pa-
tients (310 patients). Overall, the rate of no-/slow-reﬂow
was 14.5%, and in the subgroup of eligible patients at high
risk of no-/slow-reﬂow similar to the one of the imme-
diate stenting arm of the randomized study (23.4% and
28.6%, respectively). This ﬁnding conﬁrms the validity of
the criteria used for the identiﬁcation of the patients at
high risk of no-/slow-reﬂow after immediate infarct artery
stenting.
Indirectly, the study conﬁrms the inability of manual
thrombus aspiration to decrease the risk of embolization
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of both arms (>85%) received this treatment. This ﬁnding
is in several ways expected considering that manual aspi-
ration is ineffective in retrieving macroscopic debris in
approximately one-third of patients and that the high
proﬁle of the catheters increases the risk of embolization
when crossing the target lesion. Moreover, even in cases
of macrodebris aspiration, optical coherence tomography
(OCT) shows a large residual thrombus burden in the
majority of patients (5), and this explains the ineffectiveness
of manual aspiration in preventing embolism after imme-
diate stenting in patients at high risk of no-/slow-reﬂow.
Consistent with this ﬁnding is the fact that most studies on
manual aspiration have not demonstrated a reduction in
infarct size, and the largest clinical trial on manual aspira-
tion, the TASTE (Thrombus Aspiration in ST-Elevation
myocardial infarction in Scandinavia) trial, have shown no
beneﬁt of manual aspiration on clinical outcome (6). An
alternative to manual aspiration is rheolytic thrombectomy
(RT). A randomized mechanistic study comparing manual
aspiration with RT assessing residual thrombus by OCT
showed more effective thrombus removal with RT, and
patients randomized to RT after stenting had a very high
rate of TIMI ﬂow grade 3 (95%) and blush grade 3 (72%)
(5). The same TIMI blush grade 3 rate was achieved in the
JETSTENT (AngioJET Thrombectomy and STENTing
for Treatment of Acute Myocardial Infarction) trial that
compared RT plus direct stenting with direct stenting alone
(7). However, also with RT, the removal of thrombus is
incomplete in most cases (5), and it is unknown whether
the residual more organized and less friable thrombus after
RT is associated with a decreased potential for embolization
in patients at high risk of no-/slow-reﬂow.
The clinical implications of the DEFER-STEMI trial are
relevant considering that, according to the criteria used by
the DEFER-STEMI investigators for the deﬁnition of a
high risk of no-/slow-reﬂow, at least one-half of patients
with AMI could be eligible for a deferred stenting strategy.Using the short temporal window of 4 to 16 h from the
restoration of a normal ﬂow, the logistic constraints of the
application of this strategy are not insuperable. However, the
increased costs of a second procedure should be balanced
by the demonstration of improved clinical outcome by a
large clinical randomized trial.
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